BOSTON, Aug. 28, 2002 (PRIMEZONE) -- Biotechnology stocks have begun to rebound as the industry moves ahead with new products and expanded possibilities. Get the latest updates from biotech executives at the Boston Biotech Stocks Forum September 14 at the Seaport Hotel/World Trade Center - Boston.
Investors can attend this Forum either in person at the Seaport Hotel/World Trade Center - Boston or online via www.informedinvestors.com from 9:00 a.m.-11:00 a.m. EST. The Forum will give Investors the opportunity to hear directly from company executives and get their investment information straight from the source.
The Informed Investors Forum will have senior executives from Gene Logic (Nasdaq:GLGC), GlycoGenesys (Nasdaq:GLGS) and other firms speaking for approximately 30 minutes each with PowerPoint presentations. A keynote presentation by Lynn Sutherland will add perspective to the Forum. Investors are invited to submit questions directly or by email to the executives. The forum will also be archived on www.informedinvestors.com, www.vcall.com and www.investorconference.com.
Gene Logic Inc. is a leading provider of integrated genomics information and bioinformatics products and services related to the molecular basis of human disease and toxicity that enable global pharmaceutical and biotechnology companies to reduce the time, risk and cost of drug discovery and development. Through its expertise in biosamples, high-throughput genomics, data management and software development, and global sales and marketing, the Company has developed a series of genomic information solutions based on its core product, the GeneExpress(r) database.
GlycoGenesys, Inc., formerly known as SafeScience Inc., is a biotechnology company developing novel pharmaceutical products based on carbohydrate compounds. The Company's lead drug candidate, GBC-590, a potential treatment for multiple forms of cancer, is in Phase II clinical trials for pancreatic and colorectal cancers. The Company also develops agricultural products. The Company's near term objective is to continue to proceed through the various phases of United States Food and Drug Administration (FDA) clinical trials for GBC-590 and to continue to pursue federal and state registration of its agriculture products while seeking alternatives, including sale, for its agricultural products business area. GlycoGenesys conducts its business through two wholly owned subsidiaries: International Gene Group, Inc. and SafeScience Products, Inc.
Informed Investors is the leading producer of online and offline industry-specific investment conferences for individual investors and a member of the WILink suite of PrecisionIR(tm) services serving publicly traded companies and self-reliant investors.
About WILink
Since 1992, WILink plc (www.wilink.com) has helped public companies and mutual funds attract and retain investors. WILink's PrecisionIR(tm) and PrecisionFM(tm) custom investor-marketing programs enable publicly traded companies and mutual funds to deliver tailored and compelling communications to a precisely targeted audience of investors. This year WILink will make more than 7 million investor introductions for over 4,200 corporate clients through PrecisionIR(tm) and PrecisionFM(tm) programs, which include the Annual Reports Service, the Fund Info Service, Informed Investors Forums (www.informedinvestors.com) and Vcall(r) webcasting (www.vcall.com). WILink's InstitutionalReach(tm) database and partnerships with over 230 leading financial channels in 14 countries including The Wall Street Journal, Financial Times, Barron's and Yahoo! Finance ensure clients targeted visibility within the investment community. WILink, Inc. a wholly owned subsidiary of WILink plc (WLK: LSE) began operations in Richmond, Va. in 1993.